CDC Solicits Public Input on Target Product Profile for Rapid West Nile Virus Diagnostics
Federal public health authorities have initiated a critical formal step toward closing a persistent diagnostic gap in mosquito-borne illness management. On November 16, 2026, the Centers for Disease Control and Prevention (CDC), operating under the Department of Health and Human Services (HHS), published a notice in the Federal Register requesting public and expert comment on a proposed Target Product Profile (TPP) for a rapid diagnostic test for West Nile virus disease. Designed specifically for use in hospitals and clinical laboratories, the profile establishes a federal benchmark intended to stimulate commercial development of accurate and expedited testing solutions across the United States.
The Strategic Role of Target Product Profiles
In biomedical product development, a Target Product Profile functions as an authoritative planning document. It delineates the intended use, target populations, operational parameters, and both the minimally acceptable and optimal performance specifications of a medical device or diagnostic assay before full-scale commercialization occurs. By drafting and publishing this blueprint, federal health officials seek to eliminate ambiguity for medical technology manufacturers, private laboratories, and academic researchers.
The CDC aims to address an unmet clinical need. Traditional laboratory confirmation of West Nile virus can be complex and time-consuming, frequently relying on specialized testing that may delay immediate patient management decisions. Establishing clear federal benchmarks helps ensure that private industry aligns its research and development investments with real-world clinical requirements.
Statutory Framework and Administrative Oversight
The CDC is pursuing this administrative action under the explicit authority of the Public Health Service Act, specifically relying on Sections 301(a) [42 U.S.C. 241(a)] and 317U [42 U.S.C. 247b-23]. Section 301 authorizes the Secretary of HHS and subordinate agencies to conduct, promote, and coordinate public health research and technical development. Section 317U provides direct authorization for federal measures targeting vector-borne diseases and public health capacity enhancement.
The administrative proceeding is overseen by Dr. Randall Nett, Branch Chief of the Arboviral Diseases Branch within the CDC Division of Vector-Borne Diseases in Fort Collins, Colorado. The official notice was formally issued by Noah Aleshire, Chief Regulatory Officer for the agency.
Core Inquiries for Stakeholders
To ensure the final technical specifications are grounded in operational and economic realities, the CDC has structured its Request for Information around four primary questions addressed to clinicians, clinical laboratory directors, diagnostic developers, and advocacy organizations:
- Whether a rapid West Nile virus diagnostic assay would provide genuine utility for improving routine bedside clinical care.
- How an expedited test might assist investigators and physicians in evaluating prospective prophylactic measures or therapeutic treatments.
- Whether an adequate commercial market exists to support the sustainable manufacturing and distribution of such an assay by private entities.
- What specific modifications, parameters, or technical adjustments the federal government should implement prior to finalizing the profile.
By directly probing the existence of a viable commercial marketplace, the agency recognizes that regulatory clearances and federal technical guidance alone cannot succeed without sustainable commercial uptake by healthcare systems.
Public Comment Procedures and Near-Term Timelines
The agency has opened a 60-day public comment window, establishing a deadline of January 15, 2027, for all formal submissions under Docket Number CDC-2026-1684. Written contributions must be submitted via the Federal eRulemaking Portal at regulations.gov or delivered by physical mail to the Arboviral Diseases Branch in Fort Collins. The agency has stated that electronic mail submissions will not be accepted.
Submissions become part of the public administrative record and will appear on the federal portal without alteration. The agency explicitly advised contributors not to include confidential or proprietary business details in their primary submissions, directing that any sensitive business proprietary data must be compartmentalized in designated sections or separate attachments.
Following the close of the comment window, federal officials intend to review submitted data and technical recommendations to refine the TPP. The CDC anticipates publishing the finalized profile in a peer-reviewed scientific journal within six months, at which point the final document will be made accessible through the hosting journal platform to guide public health and private diagnostic manufacturing efforts nationwide.
We are not a law firm. The information on this website is for informational purposes only and may not be up to date. Always consult a licensed attorney for personalized legal advice.